Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018

London, United Kingdom (PressExposure) November 24, 2011 -- GlobalData estimates that the global brain hemorrhage therapeutics market was worth $358m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 3% to $452m by 2018. The slow growth in the brain hemorrhage therapeutics market is largely due to its stable prevalence, a high mortality rate and a weak pipeline of only two company sponsored drugs. The main risk factors associated with brain hemorrhage are lifestyle factors such as smoking, obesity and alcohol consumption. The most common therapies are prescribed off-label, such as anti-hypertensive agents (labetalol and nicardipine), hemostatic agents (vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy (mannitol 20%) which provide symptomatic treatment but lack superior safety and efficacy. The market does not have any approved therapies. These factors will result in the slow growth of the global brain hemorrhage therapeutics market to 2018.

The current brain hemorrhage therapeutics market has 17 molecules in the developmental pipeline. Most of the clinical trials are conducted by academic institutions. The only company sponsored clinical trials are GLP-1 CellBeads and PG2, sponsored by CellMed AG/BTG and PhytoHealth Corporation respectively. Of the total number of pipeline drugs, four are first-in-class and the remaining 12 are generics. The mechanism of action of one drug in Phase 0 is unknown. The first-in-class molecules have a distinct advantage over the currently marketed products with regards to better symptomatic management. Tissue Plasminogen Activator (t-PA), calcium channel blocker, synaptic vesicle protein binder, HMG-CoA reductase inhibitor, blood coagulation factor, Peroxisome Proliferator Activator Receptor (PPAR) agonist, beta adrenergic antagonist/vasodilator/Angiotensin Converting Enzyme (ACE) inhibitor, iron chelator, phosophodiesterase V inhibitor, vascular-selective L-type calcium channel antagonist and anti apoptotic are the mechanisms of action currently under investigation for brain hemorrhage. Overall, the presence of only a few first-in-class drugs and the significant presence of generics clearly suggest that the brain hemorrhage pipeline is weak and will register slow growth to 2018.

For Sample Pages, please click or add the below link to your browser: http://globaldata.com/reportstore/RequestSamplePages.aspx?ID=Brain-Hemorrhage-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=pexpo

GlobalData has found that the brain hemorrhage therapeutics market has a high level of unmet need, suggesting that the market is not well served by the current treatment options. Moreover, these treatment options are not approved and are used off-label. The market is dominated by off-label and generic medications which include antihypertensive agents, hemostatic agents, antiepileptic agents and osmotherapy. The lack of approved therapies for brain hemorrhage clearly establishes the market's high unmet need and scope for new entrants that can offer superior safety and efficacy

GlobalData, the industry analysis specialist, has released its new report, "Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global brain hemorrhage therapeutics market. The report identifies the key trends shaping and driving the global brain hemorrhage therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global brain hemorrhage sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

For further details, please click or add the below link to your browser: http://globaldata.com/reportstore/Report.aspx?ID=Brain-Hemorrhage-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&CompanyID=pexpo

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

About GlobalData

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

Press Release Source: http://PressExposure.com/PR/GlobalData.html

Press Release Submitted On: November 24, 2011 at 5:18 am
This article has been viewed 20026 time(s).